| Date | Title | Description |
| 30.10.2025 | iOrganBio: $2 Million Raised For Developing AI-Based Cell Manufacturing Solutions | iOrganBio, a biotechnology startup developing AI-based cell manufacturing solutions, has emerged from stealth with $2 million in seed funding to launch CellForge, the first artificial intelligence-powered platform for scalable and reproduci... |
| 03.02.2025 | This Startup Is Billionaire Reid Hoffman's Next Big Bet Hoffman sold LinkedIn, which he co-founded, to Microsoft for $26.2 billion in 2016. | LinkedIn co-founder Reid Hoffman became a billionaire when Microsoft bought LinkedIn in 2016 for $26.2 billion in cash, and he has also made his fortune on high-return investments in more than 80 tech startups, including Airbnb, Groupon, an... |
| 11.12.2024 | The AI Revolution: Transforming Healthcare and IT for a New Era | Artificial Intelligence (AI) is not just a buzzword; it’s a tidal wave reshaping industries. In healthcare and IT, AI is the engine driving efficiency, precision, and innovation. The transformation is profound, with each sector harnessing A... |
| 11.12.2024 | AI transforming healthcare with better outcomes & efficiency | The healthcare industry is experiencing significant changes driven by advancements in artificial intelligence (AI), which is altering how care is delivered and improving patient outcomes.
The global AI in healthcare market is on a growth pa... |
| 17.04.2024 | The Shrinking Series E: More Senior Startups Raise Smaller Follow-On Rounds | 9 Shares Email Facebook Twitter LinkedIn
Typically, when a venture-backed startup raises a follow-on round, the size of the investment and the company’s valuation go up as well.
One expects a Series D round, for instance, to be larger than ... |
| 11.03.2024 | Most-Active US Investors: Andreessen Horowitz, GV And Alumni Have Big February | 10 Shares Email Facebook Twitter LinkedIn
This is a monthly feature that runs down some of the most active investors in U.S.-based companies, looks at some of their most interesting investments, and includes some odds and ends of who spent ... |
| 05.03.2024 | The 10 Biggest Rounds Of February: Epic Games Leads The List Thanks To House Of Mouse Investment | 6 Shares Email Facebook Twitter LinkedIn
This is a monthly feature that runs down the month’s top 10 funding rounds in the U.S. Check out the biggest rounds of last month here.
February was a big month for big rounds. Companies needed to ra... |
| 27.02.2024 | Freenome scores $254M to advance its cancer-detection blood tests | The San Francisco company readies to reveal its first clinical study results in the near term
When it comes to cancer, spotting it early can make a big difference on treatment options and survival. Commonly a progressive disease, certain un... |
| 20.02.2024 | Freenome's $254M Boost for Early Cancer Detection | Freenome, a biotech company in San Francisco, just secured a massive $254M in funding to advance their blood-based cancer detection tests. The investment, led by Roche and backed by a slew of other big names, will propel Freenome's mission ... |
| 15.02.2024 | Roche leads Freenome's $254M funding round for cancer-detecting blood tests | In early 2022, Freenome surpassed $1 billion in lifetime financing after raking in two nine-figure funding rounds barely a month apart, with plans to use the money to launch new studies of its cancer blood tests.
Two years later, the compan... |
| 15.02.2024 | Freenome Raises $254M to Accelerate Early Cancer Detection Platform | What You Should Know:
– Freenome, a leader in blood-based early cancer detection, has raised $254M in a new funding round, fueled by its innovative multiomics platform and promising pipeline of tests. The funding was led by Roche with parti... |
| 15.02.2024 | Freenome Raises $254M in Funding | Freenome, a San Francisco, CA-based biotechnology company developing blood tests for early cancer detection, raised $254M in funding.
The round was led by Roche with participation from a16z Life Sciences Growth Fund, the American Cancer Soc... |
| 12.10.2023 | Bytes to Bites part three – Wellness wired: Leveraging AI to digitize nutrition and health | Editor’s Note: Eva Everloo is senior investment analyst and Dr. Anđela Martinović is scientific analyst at agrifood tech investor PeakBridge.
The views expressed in this guest commentary are the authors’ own and do not necessarily reflect t... |
| 15.06.2023 | With CVS Health’s Exit, Walgreens Steps Up Clinical Research With Cancer Test Partner | Walgreens further expanded its clinical trials and research business, partnering with biotech ... [+] company Freenome to increase "diversity in research focused on the early detection of cancer,” the companies said June 15, 2023. In t... |
| 22.05.2023 | Freenome Acquires Oncimmune | Mike Nolan, CEO of Freenome
Freenome, a South San Francisco, CA-based biotech company, acquired Oncimmune Ltd, a Nottingham, UK-based global immunodiagnostics developer with a commercialized CE-IVD marked EarlyCDT Lung blood test, autoantib... |
| 16.12.2022 | A Silicon Valley biotech just showed a simple blood test can detect a hidden and deadly type of cancer. But the results fell short of investors' hopes. | A standard blood draw. Hollis Johnson/Business Insider
Guardant Health said that its blood test to screen for cancer caught 83% of colorectal cancer cases.
Guardant says this could unlock an $20 billion market for colorectal cancer screenin... |
| 21.10.2022 | Meet Vasudev Bailey, Senior Partner at ARTIS Ventures | ARTIS invests in what it calls the TechBio space, where technology meets healthcare
Venture capital used to be a cottage industry, with very few investing in tomorrow's products and services. Oh, how times have changed! While there are more... |
| 12.09.2022 | Freenome Launches Multi-Cancer Detection Study Pairing Multiomics with Real-World Data | What You Should Know:
Freenome is a biotechnology company with a comprehensive multiomics platform for the early detection of cancer using a standard blood draw. The company combines its deep expertise in molecular biology with advanced com... |
| 12.01.2022 | Citadel Securities forms an unlikely partnership for its next big move | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Yesterday Sequoia Capital and Paradigm shared they had invested nearly $1.2 billion into Citadel ... |
| 11.01.2022 | Freenome raises $290M from Roche | Freenome said today that it has raised $290 million from Roche to advance its cancer early detection platform, which uses a routine blood draw.
The South San Francisco, California–based company has raised more than $1.1 billion since its fo... |
| 10.01.2022 | New Year, New Fund, New Opportunities in Bio + Health | 2021 saw higher than ever funding of startups, continued maturation of the tech-enabled bio and healthcare landscape, and new platforms and business models that propelled growing levels of adoption and scale amongst both upstarts and tradit... |
| 07.12.2021 | Freenome one-ups itself with $300M from GV, Roche and more to expand cancer blood test platform | In what has become a near-annual tradition for Freenome, the developer of a liquid biopsy platform for early cancer detection closed yet another venture capital megaround, sending its total fundraising tally surging to more than $800 millio... |
| 07.12.2021 | Freenome one-ups itself with $300M from GV, Roche and more to expand cancer blood test platform | In what has become a near-annual tradition for Freenome, the developer of a liquid biopsy platform for early cancer detection closed yet another venture capital megaround, sending its total fundraising tally surging to more than $800 millio... |
| 21.05.2021 | Freenome, high-profile liquid biopsy company, quietly replaces its CEO | Freenome, a high-profile startup that aims to develop a blood test to detect colon cancer, has quietly replaced its co-founder and chief executive, Gabriel Otte.
The company’s chief business officer, Mike Nolan, a long-time veteran of the g... |
| 26.08.2020 | Freenome Closes $270M Series C Financing | Freenome, a South San Francisco, Calif.-based biotechnology company, raised $270m in Series C financing.
The round was led by new investor Bain Capital Life Sciences and existing investor Perceptive Advisors. They were joined by a group of ... |
| 26.08.2020 | Freenome Secures $270M Series C To Research Cancer-Detecting Blood Tests | 7 Shares Email Facebook Twitter LinkedIn
Biotechnology company Freenome announced its largest funding round to date, an oversubscribed $270 million Series C financing, the company said Wednesday.
Subscribe to the Crunchbase Daily
The new in... |
| 26.08.2020 | Riding on early cancer detection frenzy, Freenome scores $270M to push liquid biopsy tech beyond colorectal cancer | Covid-19 and its manifold secondary effects have forced many biotech companies to adapt their clinical trials to the new normal. For Gabe Otte, it simply reinforced the importance of the tweaks Freenome was already planning... |
| 11.11.2019 | Investors just poured more than $1 billion into startups using AI to tackle every part of healthcare. Here are the 5 healthcare AI startups raking in the most cash. | Dr. Ali Parsa, the CEO of Babylon Health. Jack Lewis Williams for Tailor Made London This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
The deal count for VC-backed healthcare deals is on pa... |
| 09.10.2019 | Andreessen Horowitz hires Julie Yoo as general partner | Julie Yoo has joined Andreessen Horowitz as its newest general partner. She will make investments out of the venture capital firm’s bio fund, which closed on $450 million in 2017.
Yoo spent the last eight years as a co-founder and chief pro... |
| 26.08.2019 | ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO | → ADC Therapeutics, which last month closed its monster $303 million E round, is joining forces with Freenome, a biotech developing a diagnostic for early cancer detection through a routine blood draw. ADC will use Freenome... |
| 01.08.2019 | Freenome: This Multiomics Blood Testing Platform Raised $160 Million To Help Detect Cancer Earlier | Freenome — a biotechnology company that pioneered a multiomics platform for early cancer detection — announced it closed $160 million
Freenome — a biotechnology company that pioneered the most comprehensive multiomics platform for early can... |
| 24.07.2019 | With $160 million in new funding, Freenome looks to commercialize its blood test to detect colorectal cancer | One of the major problems that technology companies working to find a cure for cancer need to solve is finding a safe, minimally invasive way to detect cancers early.
Almost all cancer screening will eventually require a biopsy, but determi... |
| 24.07.2019 | Freenome nabs $160M to advance blood-based colorectal cancer test | Other new investors in the round include Roche Venture Fund, Kaiser Permanente Ventures and the social impact investing arm of the American Cancer Society. The company has raised a total of $238 million since its founding in 2014.
Alongside... |
| 24.07.2019 | Freenome Raises $160M in Series B Financing | Freenome, a South San Francisco, Calif.-based biotechnology company that has developed a multiomics platform for early cancer detection through a routine blood draw, closed a $160m Series B financing.
The round, which brought total financin... |
| 16.04.2019 | Guardant Health study shows liquid biopsy picking up more mutations, delivering faster results | Based on interviews with oncologists, Cannacord analyst Mark Massaro wrote in a note to clients Tuesday that the doctors indicated the NILE study “may usher in a blood-first paradigm” in testing, particularly given the ability to find more ... |
| 24.01.2019 | Alphabet’s healthcare subsidiary Verily is expanding its startup investment program | Verily Life Sciences, the healthcare subsidiary of Google’s parent company, Alphabet, is expanding the investment and collaboration program — called Partner Space — that it launched in 2017 to work with startups.
The Partner Space already h... |
| 15.05.2018 | With new $600M fund, CRV expands into bioengineering investment, adds strategic growth stage deals | In addition to bioengineering, Fund XVII will also invest in enterprise, consumer-centered companies, according to the blog entry.
Axios reported that the fund’s strategy actually marks a change from CRV’s initial plans to have a separate f... |
| 14.12.2017 | Andreessen Horowitz has a new, $450 million bio fund | Almost exactly two years ago, the venture firm Andreessen Horowitz took the wraps off a $200 million “biofund” that aimed to invest at the intersection of biology and engineering and was being led by its (then) new general partner, Vijay Pa... |
| 29.08.2017 | Term Sheet — Tuesday, August 29 | THREE THINGS
Good morning, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
Here are 3 interesting stories to start your morning:
FLUSH WITH CASH: Leonard Green & Partner will acquire CPA Global,... |
| 28.08.2017 | Freenome Raises Additional $7m in Series A Funding | Freenome, a South San Francisco, CA-based health technology company innovating disease management through non-invasive early detection and intervention, raised an additional $7m as an extension to its previously announced Series A funding.
... |
| 06.07.2017 | Report: Alphabet venture arm GV, Khosla Ventures claim top spots in healthcare investment ranks | Two investors that embrace this hybrid approach to healthcare investment also topped the category for investment volume — Alphabet’s investment arm, GV, and Khosla Ventures with seven deals apiece.
GV led or took part in healthcare investme... |
| 21.06.2017 | Andreessen Horowitz gets a new general partner in Jorge Conde | Andreessen Horowitz is making an even bigger push into healthcare IT, bringing aboard serial entrepreneur Jorge Conde as a general partner.
Conde, who officially starts in September, has spent the last 15 years working largely in genomics, ... |
| 12.05.2017 | Guardant Health adds $360 million to its war chest | Guardant Health, a four-year-old, Redwood City, Ca.-based biotech company that sells blood tests to track and potentially detect cancer, has raised a whopping $360 million from investors, bringing its total funding to $550 million. SoftBank... |
| 16.03.2017 | Advances in AI and ML are reshaping healthcare | Megh Gupta Contributor
Megh Gupta is a member of the investment team at OMERS Ventures.
Qasim Mohammad Contributor
Qasim Mohammad is a Toronto-based venture capitalist and a member of the investment team at OMERS Ventures.
More posts by thi... |
| 02.03.2017 | Term Sheet — Thursday, March 2 | BIG FOOD + SNAP
Good morning, Term Sheet readers. Today’s guest column is a doubleheader: In part one, Fortune writer John Kell looks into why Big Food wants to play the VC game; in part two, Fortune writer Jen Wieczner breaks down the bigg... |
| 01.03.2017 | GV Joins $65M Series A for Freenome | SAN FRANCISCO--(BUSINESS WIRE)--Freenome, the health technology company reinventing disease management through systematized early detection and intervention, announced today that it has raised $65 million USD in Series A funding led by Andr... |
| 01.03.2017 | In liquid biopsy race, Freenome lands $65 million, led by Andreessen Horowitz | Freenome, a two-year-old liquid biopsy diagnosis platform that detects the cell-free DNA sequencing of cancer, has raised a huge Series A round — $65 million — led by Andreessen Horowitz, which also led the company’s $5.5 million seed round... |
| 01.03.2017 | Freenome Raises $65M in Series A Funding | Freenome, a San Francisco, CA-based health technology company, raised $65m in Series A funding.
The round was led by Andreessen Horowitz with participation from Data Collective (DCVC), and Founders Fund, GV (Google Ventures), Polaris Partne... |
| 09.06.2016 | Liquid biopsy startup Freenome lands $5.5 million led by Andreessen Horowitz | Freenome, a year-old liquid biopsy diagnosis platform that detects the cell-free DNA sequencing of cancer, has landed $5.5 million in seed funding led by Andreessen Horowitz, with participation from Founders Fund, Data Collective, and Third... |
| 09.06.2016 | Early-Detection Cancer Test Developer Freenome Raises $5.6M | Freenome, a Palo Alto, CA-based developer of early-detection cancer tests, raised $5.6m in seed funding.
The round was led by Andreessen Horowitz, with participation from Founders Fund, Data Collective Venture Capital, and Third Kind Ventur... |
| - | Guardant Health study shows liquid biopsy picking up more mutations, delivering faster results | Published results of a liquid biopsy study in lung cancer patients could lead oncologists to prioritize blood-based genomic sequencing over traditional tissue testing.
Redwood City, California-based Guardant Health said Monday that it had p... |
| - | Report: Alphabet venture arm GV, Khosla Ventures claim top spots in healthcare investment ranks | Healthcare investments hit $3.8 billion in the second quarter of 2017, marking a spike in these deals and a milestone for the healthcare industry in general, according to StartUp Health’s half year report. The trend of fewer deals but with ... |
| - | Freenome nabs $160M to advance blood-based colorectal cancer test | Investors have poured boatloads of cash into liquid biopsy companies promising that their technology is the solution for non-invasive screening of early-stage cancer.
In the latest mega funding round, South San Francisco company Freenome ha... |
| - | Freenome | “Freenome is a private biotech company focused on developing blood tests to detect cancer early and make screening accessible for everyone.” |
| - | Freenome | “Home | Freenome” |
| - | With new $600M fund, CRV expands into bioengineering investment, adds strategic growth stage deals | Early stage venture capital firm CRV has closed a $600 million fund that accomplishes a couple of firsts for the venture firm. The fund will embrace strategic growth stage investments as well as early-stage deals and adds bioengineering to ... |
| - | BrightEdge joins world class investors to help accelerate early detection technology | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw, today announced the close of its $160 mil... |
